Millennium Management Llc Sells 7,666 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.12, for a total value of $246,231.92. Following the completion of the sale, the insider owned 144,974 shares of the company’s stock, valued at approximately $4,656,564.88. The trade was a 5.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc bought 9,533 shares of Sensei Biotherapeutics stock. The stock was acquired at an average price of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc bought 15,321 shares of Sensei Biotherapeutics stock. The stock was acquired at an average price of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc bought 5,731 shares of Sensei Biotherapeutics stock. The stock was acquired at an average price of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc bought 6,175 shares of Sensei Biotherapeutics stock. The shares were purchased at an average cost of $34.49 per share, for a total transaction of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc bought 6,005 shares of Sensei Biotherapeutics stock. The shares were purchased at an average cost of $28.16 per share, for a total transaction of $169,100.80.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ:SNSE traded up $0.61 during trading on Friday, reaching $20.43. 40,084 shares of the stock were exchanged, compared to its average volume of 223,112. Sensei Biotherapeutics, Inc. has a 1-year low of $5.25 and a 1-year high of $36.76. The stock has a fifty day moving average of $29.11 and a two-hundred day moving average of $17.85. The firm has a market cap of $27.40 million, a price-to-earnings ratio of -1.23 and a beta of -0.18.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). Sell-side analysts forecast that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,041 shares of the company’s stock after buying an additional 20,525 shares during the quarter. Renaissance Technologies LLC owned 2.39% of Sensei Biotherapeutics worth $1,010,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

SNSE has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Leerink Partners started coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $40.00.

Sensei Biotherapeutics News Roundup

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.